Clinical Research Directory
Browse clinical research sites, groups, and studies.
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
Sponsor: Supernus Pharmaceuticals, Inc.
Summary
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
Official title: An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-07-30
Completion Date
2027-12-31
Last Updated
2026-10-27
Healthy Volunteers
No
Conditions
Interventions
SPN-817
SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
Locations (8)
Center for Neurosciences
Tucson, Arizona, United States
Focus Clinical Research
West Hills, California, United States
Ilumina Medical Research
Kissimmee, Florida, United States
Medsol Clinical Research Center
Port Charlotte, Florida, United States
University of Rochester Medical Center
Rochester, New York, United States
Asheville Neurology Specialists
Asheville, North Carolina, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
The Alfred Hospital
Melbourne, Victoria, Australia